Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.

Eli Lilly will announce Q4 2024 results, with analysts estimating $13.7 billion in sales and $4.94 EPS, alongside a revenue growth outlook for 2024.

The discontinuation comes after the investigational drug, volenrelaxin, failed a related heart failure study in an ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Eli Lilly, the world’s largest drugmaker by market value, is in advanced talks to buy cancer-focused ...

Eli Lilly and venture capital firm Andreessen Horowitz ... s R&D expertise to “foster a technology ecosystem of ambitious bio + health entrepreneurs and innovators,” according to a Jan ...